Características de las pacientes con cáncer de ovario en el Hospital de San José, Bogotá D.C., 2009-2013

Autores:: Mora Padilla, Edmundo
Gutiérrez Rodríguez, Everardo

Tipo de recurso:: Article of journal

Fecha de publicación:: 2016

Institución:: Fundación Universitaria de Ciencias de la Salud - FUCS

Repositorio:: Repositorio Digital Institucional ReDi

Idioma:: spa

id	FUCS2_abc9b502b77d6faa32d2b722692a837f
oai_identifier_str	oai:repositorio.fucsalud.edu.co:001/2045
network_acronym_str	FUCS2
network_name_str	Repositorio Digital Institucional ReDi
repository_id_str
dc.title.spa.fl_str_mv	Características de las pacientes con cáncer de ovario en el Hospital de San José, Bogotá D.C., 2009-2013
dc.title.translated.eng.fl_str_mv	Profile of patients with ovarian cancer in the Hospital de San José, Bogota, 2009-2013
title	Características de las pacientes con cáncer de ovario en el Hospital de San José, Bogotá D.C., 2009-2013
spellingShingle	Características de las pacientes con cáncer de ovario en el Hospital de San José, Bogotá D.C., 2009-2013 Cáncer de ovario Citorreducción Neoadyuvancia Recurrencia Mortalidad Ovarian cancer Cytoreduction Neoadjuvant Recurrence Mortality
title_short	Características de las pacientes con cáncer de ovario en el Hospital de San José, Bogotá D.C., 2009-2013
title_full	Características de las pacientes con cáncer de ovario en el Hospital de San José, Bogotá D.C., 2009-2013
title_fullStr	Características de las pacientes con cáncer de ovario en el Hospital de San José, Bogotá D.C., 2009-2013
title_full_unstemmed	Características de las pacientes con cáncer de ovario en el Hospital de San José, Bogotá D.C., 2009-2013
title_sort	Características de las pacientes con cáncer de ovario en el Hospital de San José, Bogotá D.C., 2009-2013
dc.creator.fl_str_mv	Mora Padilla, Edmundo Gutiérrez Rodríguez, Everardo
dc.contributor.author.spa.fl_str_mv	Mora Padilla, Edmundo Gutiérrez Rodríguez, Everardo
dc.subject.spa.fl_str_mv	Cáncer de ovario Citorreducción Neoadyuvancia Recurrencia Mortalidad
topic	Cáncer de ovario Citorreducción Neoadyuvancia Recurrencia Mortalidad Ovarian cancer Cytoreduction Neoadjuvant Recurrence Mortality
dc.subject.eng.fl_str_mv	Ovarian cancer Cytoreduction Neoadjuvant Recurrence Mortality
publishDate	2016
dc.date.accessioned.none.fl_str_mv	2016-03-01 00:00:00 2022-02-21T20:33:32Z
dc.date.issued.none.fl_str_mv	2016-03-01
dc.date.available.none.fl_str_mv	2016-03-01 00:00:00 2022-02-21T20:33:32Z
dc.type.spa.fl_str_mv	Artículo de revista
dc.type.eng.fl_str_mv	Journal article
dc.type.coar.fl_str_mv	http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.coar.spa.fl_str_mv	http://purl.org/coar/resource_type/c_6501
dc.type.driver.spa.fl_str_mv	info:eu-repo/semantics/article
dc.type.version.spa.fl_str_mv	info:eu-repo/semantics/publishedVersion
dc.type.content.spa.fl_str_mv	Text
dc.type.coarversion.spa.fl_str_mv	http://purl.org/coar/version/c_970fb48d4fbd8a85
format	http://purl.org/coar/resource_type/c_6501
status_str	publishedVersion
dc.identifier.issn.none.fl_str_mv	0121-7372
dc.identifier.uri.none.fl_str_mv	https://repositorio.fucsalud.edu.co/handle/001/2045
dc.identifier.eissn.none.fl_str_mv	2462-991X
dc.identifier.url.none.fl_str_mv	https://revistas.fucsalud.edu.co/index.php/repertorio/article/view/67
identifier_str_mv	0121-7372 2462-991X
url	https://repositorio.fucsalud.edu.co/handle/001/2045 https://revistas.fucsalud.edu.co/index.php/repertorio/article/view/67
dc.language.iso.spa.fl_str_mv	spa
language	spa
dc.relation.references.spa.fl_str_mv	World Health Organization, International Agency for Research on Cancer. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. [Internet] Ginebra: World Health Organization [citado 10 Feb 2015]. Disponible en: http://globocan., iarc., fr/Default, aspx. Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013;132:1133–45. Prat J. Oncology FCoG. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2014;124:1–5. MW G. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology. 2011;43:420–32. Schorge JO, Modesitt SC, Coleman RL, Cohn DE, Kauff ND, Duska LR, et al. SGO white paper on ovarian cancer: Etiology, screening and surveillance. Gynecol Oncol. 2010;119:7–17. Shih KR. Ovarian tumorigenesis. A proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004;164:1511–8. Kaye S, Brown R, Gabra H, Gore ME, editores. Emerging therapeutic targets in ovarian cancer. New York: Springer Science; 2011. p. 278. Di Saia PJ, Creasman WT. Clinical gynecologic oncology. Philadelphia, PA: Elsevier; 2007. Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, et al. Carcinoma of the ovary. FIGO 26th Annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 2006;95 Suppl 1:S161–92. Tavassoli FA, Devilee P. Pathology and genetics of tumours of the breast and female genital organs. Lyon: IAPS Press; 2003. p. 432. Berek JS, Hacker NF. Berek & Hacker’s gynecologic oncology. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins Health; 2010. Giede KK, Dodge J, Rosen B. Who should operate on patients with ovarian cancer? An evidence-based review. Gynecol Oncol. 2005;99:447–61. Jacobs OD, Faibanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating ultrasound and menopausal status for the preoperative diagnosis of ovarian cancer. BJOG. 1990;97:922–9. American College of Obstetricians and Gynecologists, Committee on Gynecologic Practice. Committee opinion n. o 477: The role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer. Obstet Gynecol. 2011;117(3):742-6. Dearking AC, Aletti GD, McGree ME, Weaver AL, Sommerfield MK, Cliby WA. How relevant are ACOG and SGO guidelines for referral of adnexal mass? Obstet Gynecol. 2007;110:841–8. Ueland FR, Desimone CP, Seamon LG, Miller RA, Goodrich S, Podzielinski I, et al. Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors. Obstet Gynecol. 2011;117:1289–97. Galgano MT, Hampton GM, Frierson HF Jr. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol. 2006;19:847–53. Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009;112:40–6. Van Gorp T, Cadron I, Despierre E, Daemen A, Leunen K, Amant F, et al. HE4 and CA125 as a diagnostic test in ovarian cancer: Prospective validation of the risk of ovarian malignancy algorithm. Br J Cancer. 2011;104:863–70. Karlsen MA, Sandhu N, Hogdall C, Christensen IJ, Nedergaard L, Lundvall L, et al. Evaluation of HE4. CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2012;127:379–83. Du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: By the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer. 2009;115:1234–44. Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943–53. van der Burg ME, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med. 1995;332:629–34. National Comprehensive Cancer Network. NCCN Guidelines. [Internet] Fort Washington: National Comprehensive Cancer Network [citado 15 Oct 2015]. Disponible en: http://www. nccn.org/professionals/physician gls/f guidelines.asp Titus-Ernstoff L, Perez K, Cramer DW, Harlow BL, Baron JA, Greenberg ER. Menstrual and reproductive factors in relation to ovarian cancer risk. Br J Cancer. 2001;84:714–21. Protani MM, Nagle CM, Webb PM. Obesity and ovarian cancer survival: A systematic review and meta-analysis. Cancer Prev Res (Phila). 2012;5:901–10. Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine DA, et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009;114:26–31.
dc.relation.bitstream.none.fl_str_mv	https://revistas.fucsalud.edu.co/index.php/repertorio/article/download/67/55
dc.relation.citationedition.spa.fl_str_mv	Núm. 1 , Año 2016 : Enero – Marzo
dc.relation.citationendpage.none.fl_str_mv	21
dc.relation.citationissue.spa.fl_str_mv	1
dc.relation.citationstartpage.none.fl_str_mv	15
dc.relation.citationvolume.spa.fl_str_mv	25
dc.relation.ispartofjournal.spa.fl_str_mv	Revista Repertorio de Medicina y Cirugía
dc.rights.spa.fl_str_mv	Fundación Universitaria de Ciencias de la Salud-FUCS - 2016
dc.rights.accessrights.spa.fl_str_mv	info:eu-repo/semantics/openAccess
dc.rights.uri.spa.fl_str_mv	https://creativecommons.org/licenses/by-nc-sa/4.0/
dc.rights.coar.spa.fl_str_mv	http://purl.org/coar/access_right/c_abf2
rights_invalid_str_mv	Fundación Universitaria de Ciencias de la Salud-FUCS - 2016 https://creativecommons.org/licenses/by-nc-sa/4.0/ http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv	openAccess
dc.format.mimetype.spa.fl_str_mv	application/pdf
dc.publisher.spa.fl_str_mv	Sociedad de Cirugía de Bogotá, Hospital de San José y Fundación Universitaria de Ciencias de la Salud
dc.source.spa.fl_str_mv	https://revistas.fucsalud.edu.co/index.php/repertorio/article/view/67
institution	Fundación Universitaria de Ciencias de la Salud - FUCS
bitstream.url.fl_str_mv	https://repositorio.fucsalud.edu.co/bitstreams/c621dad4-2123-4a73-bc62-6099fe6b5db5/download
bitstream.checksum.fl_str_mv	b6a38072a2908b19b9175261ebe60602
bitstream.checksumAlgorithm.fl_str_mv	MD5
repository.name.fl_str_mv	Repositorio Digital de la Fundación Universitaria de Ciencias de la Salud
repository.mail.fl_str_mv	redi@fucsalud.edu.co
_version_	1808413873590501376
spelling	Mora Padilla, Edmundo7d8893a2c8f1f299ecc527351c9d9af3500Gutiérrez Rodríguez, Everardoe0793284e1da09f81169738f101817a63002016-03-01 00:00:002022-02-21T20:33:32Z2016-03-012016-03-01 00:00:002022-02-21T20:33:32ZSociedad de Cirugía de Bogotá, Hospital de San José y Fundación Universitaria de Ciencias de la SaludFundación Universitaria de Ciencias de la Salud-FUCS - 2016info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/4.0/http://purl.org/coar/access_right/c_abf2https://revistas.fucsalud.edu.co/index.php/repertorio/article/view/67Cáncer de ovarioCitorreducciónNeoadyuvanciaRecurrenciaMortalidadOvarian cancerCytoreductionNeoadjuvantRecurrenceMortalityCaracterísticas de las pacientes con cáncer de ovario en el Hospital de San José, Bogotá D.C., 2009-2013Profile of patients with ovarian cancer in the Hospital de San José, Bogota, 2009-2013application/pdfArtículo de revistaJournal articlehttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionTexthttp://purl.org/coar/version/c_970fb48d4fbd8a850121-7372https://repositorio.fucsalud.edu.co/handle/001/20452462-991Xhttps://revistas.fucsalud.edu.co/index.php/repertorio/article/view/67spaWorld Health Organization, International Agency for Research on Cancer. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. [Internet] Ginebra: World Health Organization [citado 10 Feb 2015]. Disponible en: http://globocan., iarc., fr/Default, aspx.Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013;132:1133–45.Prat J. Oncology FCoG. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2014;124:1–5.MW G. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology. 2011;43:420–32.Schorge JO, Modesitt SC, Coleman RL, Cohn DE, Kauff ND, Duska LR, et al. SGO white paper on ovarian cancer: Etiology, screening and surveillance. Gynecol Oncol. 2010;119:7–17.Shih KR. Ovarian tumorigenesis. A proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004;164:1511–8.Kaye S, Brown R, Gabra H, Gore ME, editores. Emerging therapeutic targets in ovarian cancer. New York: Springer Science; 2011. p. 278.Di Saia PJ, Creasman WT. Clinical gynecologic oncology. Philadelphia, PA: Elsevier; 2007.Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, et al. Carcinoma of the ovary. FIGO 26th Annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 2006;95 Suppl 1:S161–92.Tavassoli FA, Devilee P. Pathology and genetics of tumours of the breast and female genital organs. Lyon: IAPS Press; 2003. p. 432.Berek JS, Hacker NF. Berek & Hacker’s gynecologic oncology. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins Health; 2010.Giede KK, Dodge J, Rosen B. Who should operate on patients with ovarian cancer? An evidence-based review. Gynecol Oncol. 2005;99:447–61.Jacobs OD, Faibanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating ultrasound and menopausal status for the preoperative diagnosis of ovarian cancer. BJOG. 1990;97:922–9.American College of Obstetricians and Gynecologists, Committee on Gynecologic Practice. Committee opinion n. o 477: The role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer. Obstet Gynecol. 2011;117(3):742-6.Dearking AC, Aletti GD, McGree ME, Weaver AL, Sommerfield MK, Cliby WA. How relevant are ACOG and SGO guidelines for referral of adnexal mass? Obstet Gynecol. 2007;110:841–8.Ueland FR, Desimone CP, Seamon LG, Miller RA, Goodrich S, Podzielinski I, et al. Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors. Obstet Gynecol. 2011;117:1289–97.Galgano MT, Hampton GM, Frierson HF Jr. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol. 2006;19:847–53.Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009;112:40–6.Van Gorp T, Cadron I, Despierre E, Daemen A, Leunen K, Amant F, et al. HE4 and CA125 as a diagnostic test in ovarian cancer: Prospective validation of the risk of ovarian malignancy algorithm. Br J Cancer. 2011;104:863–70.Karlsen MA, Sandhu N, Hogdall C, Christensen IJ, Nedergaard L, Lundvall L, et al. Evaluation of HE4. CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2012;127:379–83.Du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: By the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer. 2009;115:1234–44.Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943–53.van der Burg ME, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med. 1995;332:629–34.National Comprehensive Cancer Network. NCCN Guidelines. [Internet] Fort Washington: National Comprehensive Cancer Network [citado 15 Oct 2015]. Disponible en: http://www. nccn.org/professionals/physician gls/f guidelines.aspTitus-Ernstoff L, Perez K, Cramer DW, Harlow BL, Baron JA, Greenberg ER. Menstrual and reproductive factors in relation to ovarian cancer risk. Br J Cancer. 2001;84:714–21.Protani MM, Nagle CM, Webb PM. Obesity and ovarian cancer survival: A systematic review and meta-analysis. Cancer Prev Res (Phila). 2012;5:901–10.Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine DA, et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009;114:26–31.https://revistas.fucsalud.edu.co/index.php/repertorio/article/download/67/55Núm. 1 , Año 2016 : Enero – Marzo2111525Revista Repertorio de Medicina y CirugíaPublicationOREORE.xmltext/xml2604https://repositorio.fucsalud.edu.co/bitstreams/c621dad4-2123-4a73-bc62-6099fe6b5db5/downloadb6a38072a2908b19b9175261ebe60602MD51001/2045oai:repositorio.fucsalud.edu.co:001/20452024-02-02 13:08:23.212https://creativecommons.org/licenses/by-nc-sa/4.0/Fundación Universitaria de Ciencias de la Salud-FUCS - 2016metadata.onlyhttps://repositorio.fucsalud.edu.coRepositorio Digital de la Fundación Universitaria de Ciencias de la Saludredi@fucsalud.edu.co

Características de las pacientes con cáncer de ovario en el Hospital de San José, Bogotá D.C., 2009-2013

Publicaciones similares